KD Logo

Alto Neuroscience Inc [ANRO] CHIEF MEDICAL OFFICER makes an insider purchase of 12,069 shares worth 0.15 million.

Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Alto Neuroscience Inc shares valued at $152,085 were purchased by Savitz Adam on Jul 09 ’24. At $12.60 per share, Savitz Adam acquired 12,069 shares. The insider’s holdings grew to 36,920 shares worth approximately $0.15 million following the completion of this transaction.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Also, Savitz Adam purchased 2,931 shares, netting a total of over 38,748 in proceeds. Following the buying of shares at $13.22 each, the insider now holds 39,851 shares.

Before that, Smith Nicholas Conrad had added 6,150 shares to its account. In a trade valued at $100,628, the CHIEF FINANCIAL OFFICER bought Alto Neuroscience Inc shares for $16.36 each. Upon closing the transaction, the insider’s holdings increased to 6,150 shares, worth approximately $0.11 million.

As published in a research note from Wedbush on October 23, 2024, Alto Neuroscience Inc [ANRO] has been rated down from an Outperform to a Neutral and the price target has been revised to $4 from $29. Analysts at Rodman & Renshaw downgraded the stock from ‘”a Buy”‘ to ‘”a Neutral”‘ outlook in a report released in late October. As of September 03, 2024, Wedbush has initiated its “an Outperform” rating for ANRO. Earlier on February 27, 2024, William Blair initiated its rating. Their recommendation was “an Outperform” for ANRO stock.

Analyzing ANRO Stock Performance

During the last five days, there has been a drop of approximately -11.09%. Over the course of the year, Alto Neuroscience Inc shares have dropped approximately -80.24%. A 50-day SMA is recorded $8.96, while a 200-day SMA reached $12.13. Nevertheless, trading volume fell to 0.78 million shares from 0.36 million shares the previous day.

Support And Resistance Levels for Alto Neuroscience Inc (ANRO)

According to the 24-hour chart, there is a support level at 3.85, which, if violated, would cause prices to drop to 3.60. In the upper region, resistance lies at 4.33. The next price resistance is at 4.57. RSI (Relative Strength Index) is 30.48 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.00, which suggests the price will decrease in the coming days. Percent R is at 64.96%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.

Most Popular